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Abstract
Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized 
that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively 
recognizes transduced T cells and tumor cells would improve T cell recruitment to tumors and enhance therapeutic efficacy.
Methods: SV40 T antigen–specific T cells from T cell receptor (TCR)-I–transgenic mice were transduced with a truncated human 
epidermal growth factor receptor (EGFR) as a marker protein. Targeting and killing by combined ACT and anti-EGFR–anti-EpCAM 
BiAb therapy was analyzed in C57Bl/6 mice (n = six to 12 per group) carrying subcutaneous tumors of the murine gastric cancer cell 
line GC8 (SV40+ and EpCAM+). Anti-EGFR x anti-c-Met BiAb was used for targeting of human tumor-specific T cells to c-Met+ human 
tumor cell lines. Differences between experimental conditions were analyzed using the Student’s t test, and differences in tumor 
growth with two-way analysis of variance. Overall survival was analyzed by log-rank test. All statistical tests were two-sided.
Results: The BiAb linked EGFR-transduced T cells to tumor cells and enhanced tumor cell lysis. In vivo, the combination of 
ACT and Biab produced increased T cell infiltration of tumors, retarded tumor growth, and prolonged survival compared 
with ACT with a control antibody (median survival 95 vs 75 days, P < .001). In human cells, this strategy enhanced 
recruitment of human EGFR–transduced T cells to immobilized c-Met and recognition of tyrosinase+ melanoma cells by 
TCR-, as well as of CEA+ colon cancer cells by chimeric antigen receptor (CAR)–modified T cells.
Conclusions: BiAb recruitment of tumor-specific T cells transduced with a marker antigen to tumor cells may enhance 
efficacy of ACT.
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Tumor antigen–specific T cells are attractive tools for 
cancer therapy, because they are highly specific (1), can 
actively infiltrate tumor tissue where their target antigen 
is expressed (2), and are capable of serial-target cell killing 
(3). However, efficacy of T cell therapy against solid tumors 
without host conditioning is limited, and this treatment only 
leads to responses in a small subset of patients (two out of 
11) (4).
Host conditioning with total body irradiation or T cell–
depleting chemotherapy has been investigated to improve 
the therapeutic efficacy of adoptive T cell therapy (ACT) (5). 
However, these treatments are accompanied by frequent 
high-grade (3 or 4)  toxicities, limiting their use to restricted 
patient populations (6). Thus, there is a need for strategies 
addressing the inherent limitations of ACT without causing 
severe side effects.
Bispecific antibodies (BiAbs) with specificity against a 
tumor-associated antigen and against a T cell marker are cur-
rently in clinical development to recruit T cells to cancer cells 
(7,8). Most T cell–recruiting BiAb address T cells by the pan-T 
cell marker CD3. They have proven their efficacy in clinical 
phase II (7) and III trials (9). The combination of ACT with BiAb 
application is an attractive strategy to enhance the efficacy of 
either approach alone, but so far have yielded disappointing 
results because of the induction of a cytokine storm upon T 
cell activation (10).
Because of the ability of BiAbs to link T cells with tumor cells, 
we hypothesized that a nonsignaling (inert) antigen introduced 
into the tumor-reactive T cell could be used as the target for one 
binding arm of a BiAb (Figure 1). In contrast to using an anti-
CD3 BiAb, T cell activation in this setting can only result from 
T cell receptor (TCR) engagement. Thus T cell degranulation 
can only occur at the tumor site and not systemically in other 
organs or in the circulation. Combining ACT of tumor-specific 
T cells expressing an inert marker antigen with a cognate BiAb 
recognizing both the transduced T cell and a tumor antigen has 
the potential to facilitate tumor-specific T cell engagement in 
the tumor tissue while avoiding systemic T cell activation by 
functionally separating the linking of T cells to tumors and T 
cell activation.
Methods
Animal Experiments
Wild-type C57BL/6RJ mice were purchased from Janvier (St. 
Berthevin, France). Mice transgenic for a T cell receptor specific 
for the immunodominant epitope I of the simian virus 40 (SV40) T 
antigen (TCR-I) were purchased from the Jackson Laboratory (stock 
number 005236). mGC8 tumors were induced subcutaneously with 
3 x 106 cells. Prior to treatment, mice were randomized to the treat-
ment groups (n = six to 12 per group), and tumors were measured 
every other day in a nonblinded fashion. Tumor volume was esti-
mated using the following formula: V = 4/3 x π x L1
2 x L2 (with L1 
defined as maximal diameter and L2, the diameter perpendicular to 
L1). T cells and antibodies were given intravenous (i.v.). All animal 
studies were approved by the local regulatory agency (Regierung von 
Oberbayern). Power calculations were done prior to study approval.
T Cell Transduction
Truncated human epithelial growth factor receptor (referred to 
as ΔEGFR), comprising amino acids 1–667, was cloned into the 
retroviral vector pMP71 (kindly provided by C. Baum, Hannover, 
Germany) and into the retroviral bicistronic pBULLET vector 
containing BW431/26-scFv-Fc-CD28-CD3 CAR specific for CEA 
(11). pMP71-ΔEGFR was used for transduction of human and 
murine wild-type T cells, the murine T cell line B3Z, the human 
tyrosinase specific T cell clone IVSB and the human T cell line 
Jurkat. For human CEA–CAR T cell transduction, the pBULLET 
vector was used. Transduction protocols have been described 
in detail (11–13). In brief, Plat-E cells were transfected and the 
produced retrovirus was used to transduce murine T cells pres-
timulated by anti-CD3 and anti-CD28 antibodies (eBioscience, 
Frankfurt, Germany, clones 145-2C11 and 37.51, respectively) 
and IL-2 (10 IU/mL). In subsequent cultures, anti-CD3, anti-
CD28 beads (Life Technologies, Carlsbad, CA), and IL-15 (50 ng/
mL, Peprotech, Hamburg, Germany) were applied. For human T 
cell transduction, 293T cells were transfected with the respec-
tive retroviral vector together with the plasmids pcDNA3.1-
MLVg/p and pALF10A1 (both kindly provided by W. Uckert, Max 
Delbruck Centre, Berlin). Retrovirus was used to transduce 
Figure 1. Schematic diagram of bispecific antibody-enhanced binding of tumor antigen–specific T cells to tumor cells. The anti–epidermal growth factor receptor 
(EGFR) x anti-EpCAM bispecific antibody (ER-Ep BiAb) in a two-plus-two format contains two binding sites for EpCAM (rat antimurine EpCAM – disulphide stabilized 
ScFv – VH – (G4S)3-VL), which is expressed on the tumor cell surface, and two binding sites for a truncated form of EGFR (ΔEGFR) which is expressed by the transduced 
T cells. The T cell receptor of the transduced T cells is specific for the immunodominant epitope-1 of the SV40 large T antigen, which is presented in the context of 
major histocompatibility complex (MHC) class I by the tumor cell. Cross-linking by anti-EGFR x anti-EpCAM bispecific antibody may increase or stabilize T cell–tumor 
cell contact established by the T cell receptor–MHC class I interaction.
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primary human T cells or the IVSB clone. Primary human T 
cells were stimulated using anti-CD3 and anti-CD28 antibod-
ies (ebioscience, clones HIT3a and CD28.2, respectively) and IL-2 
(200 U/mL).
Antibody Cross-Linking Assay
Epithelial cell adhesion molecule (EpCAM+) 4T1 were seeded 
and grown to confluence. ΔEGFR-transduced B3Z T cells were 
labeled with calcein (Life Technologies, Carlsbad, CA) and loaded 
with anti-EGFR–anti-EpCAM BiAb (ER-Ep BiAb) or control anti-
EGFR–anti-digoxigenin BiAb (ER-Dig BiAb). For human T cells, 
ΔEGFR-transduced, calcein-labeled Jurkat T cells preloaded 
with anti-EGFR–anti-c-Met BiAb (ER-Met BiAb) were incu-
bated on recombinant c-Met (R & D, Wiesbaden-Nordenstadt, 
Germany)–coated plates. The plate was washed and cells were 
visualized by fluorescence microscopy. Calcein retention was 
measured using a Mithras multilabel reader (Berthold, Bad 
Wildbad, Germany). Percentage of retained cells was normal-
ized to total cell input.
Killing Assay
mGC8 murine gastric cancer cells were labeled with calcein. 
ΔEGFR-transduced T cells were preloaded with ER-Ep BiAb or 
control ER-Dig BiAb and cocultured with tumor cells. Calcein 
mean fluorescence intensity (cMFI) in the supernatant was 
quantified. Specific lysis (%) was calculated as (cMFIof interest - 
cMFIbackground)/(cMFItotal lysis - cMFIbackground) x 100%.
Interferon-γ Release Assay
ΔEGFR-transduced IVSB T cell clone and ΔEGFR-
carcinoembryonic antigen (CEA)–chimeric antigen receptor 
(CAR)–transduced T cells were cocultivated with mel624.38 
and MelA375 or LS174T for 48 hours at a ratio of 10:1 or 1:2.5, 
respectively. IFN-γ release was quantified by enzyme-linked 
immunosorbent assay (ELISA; R & D). For IVSB T cell clone 
experiments, the coculture was preceded by cell adhesion of 
transduced and untransduced T cells using anti-EGFR antibody 
AY13 (Biolegend, London, UK) labeled with APC and anti-APC 
magnetic cell sorting (Miltenyi, Bergisch-Gladbach, Germany); 
retained cells were used for the assay. For CEA-CAR experi-
ments, T cells were preloaded with ER-Met BiAb for 30 minutes 
prior to coculture.
Statistical Analysis
For statistics, GraphPad Prism software version 5.0b was used. 
All variables reported are continuous. For in vitro analysis, dif-
ferences between experimental conditions were analyzed using 
the unpaired two-sided Student’s t test; P values under .05 
were considered statistically significant. For in vivo data, dif-
ferences between groups were analyzed using two-way analy-
sis of variance (ANOVA) with correction for multiple testing by 
the Bonferroni method. For tumor growth analysis, D’Agostino 
Pearson omnibus normality analysis was performed on 21 
tumor-bearing but untreated mice (620 ± 619 mm2, P = .021); thus, 
normality of tumor growth distribution was assumed. Overall 
survival was analyzed by log-rank test. Survival is defined in 
days from tumor induction until natural death or until mice 
were killed because one of the following criteria was reached: 
tumor size greater than 225 mm2, weight loss greater than 15% 
or prolonged distress, as defined by the German Society for 
Laboratory Animal Science. Data are shown as mean values of 
a minimum of three biological replicates or independent experi-
ments ± standard deviation.
Results
Murine EpCAM and Human EGFR as Model Targets 
in a Syngeneic Murine Tumor Model
To test our hypothesis of enhancing T cell to tumor binding 
by BiAbs, we used mGC8 gastric cancer cells as target cells 
or for inducing subcutaneous tumors. mGC8 cells are posi-
tive for murine EpCAM on the cell surface (Supplementary 
Figure 1A, available online) and present the immunodominant 
epitope of the SV40 T antigen in the context of H-2 Kd (14). To 
assess whether EpCAM would be amenable to antibody-based 
therapy, we injected tumor-bearing mice with the monoclo-
nal rat anti-EpCAM antibody G8.8. Deposition of this antibody 
was detected by direct immunofluorescence in the tumor and 
in all organs found positive for EpCAM by expression analy-
sis (Supplementary Figure 1, B and C). Human EGFR was used 
because of lack of cross-reactivity of the anti-EGFR antibody 
cetuximab (Mab225) with murine tissue (15). Thus, Mab225 did 
not detect the cell line mGC8 and did not react to any of the 
tested organs (tumor, spleen, liver, lung, kidney, and bowel, data 
not shown).
Generation of a Novel Anti-EGFR x Anti-EpCAM  
(ER-Ep) BiAb
We generated a novel BiAb-binding EGFR and murine EpCAM 
ectodomains with similar affinity as compared with the mono-
clonal parental antibodies (Figure 1 and Table 1). The ER-Ep BiAb 
is not cross-reactive to murine EGFR and thus does not bind to 
the cell line mGC8 used in this study. Surface plasmon reso-
nance analysis confirmed that the BiAb was able to bind both 
antigens simultaneously (Table  1; Supplementary Figure  2A, 
available online). The ER-Ep BiAb did not induce statistically 
significant antibody-dependent cellular cytotoxicity or comple-
ment dependent cytotoxicity (data not shown).
Cross-Linking of ΔEGFR+ T Cells With EpCAM+ Tumor 
Cells and Directed Killing of Tumor Cells
The ΔEGFR construct was used to stably transduce T cells 
(for representative transduction result see Supplementary 
Figure  2B, available online). The ability of the ER-Ep BiAb to 
bring ΔEGFR-transduced T cells and EpCAM+ tumor cells into 
physical proximity was addressed in vitro. The ER-Ep BiAb 
retained more ΔEGFR+ T cells in proximity to the tumor cells 
compared with control ER-Dig BiAb, which binds only to EGFR 
(mean retention ± SD 87 % ± 13 % vs 24% ± 8 %, P = .002) and to 
incubation without antibody (87 % ± 13 % vs 9 ± 3 %, P < .001) 
(Figures 2, A, B, and C). Remarkably, this ability to link T cells 
to tumor cells resulted in lysis of the target cells, with a maxi-
mal lysis at a E:T ratio of 10:1 (TCR-I + ER-Ep BiAb + mGC8 vs 
TCR-I + ER-Dig BiAb + mGC8, 83 ± 12 % vs -18.5 ± 1%, P < .001) 
(Figure 2D). Lysis was dependent on the simultaneous presence 
of the four interacting components: ΔEGFR and TCR-I targeting 
SV40 T antigen on the T cells; EpCAM and SV40 T antigen on 
the tumor cells (Figure 2D; Supplementary Table 1 for P values, 
available online).
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Impact of ER-Ep BiAb and ΔEGFR+ TCR Transgenic  
T Cells on mGC8 Tumor Growth
Therapeutic efficacy of the combination of the ER-Ep BiAb and 
ACT was investigated in mice carrying subcutaneous mGC8 
tumors. The combined treatment ER-Ep BiAb plus ΔEGFR+ TCR-I 
T cells of mice with established tumors (mean size at onset 
133 mm3) delayed tumor growth as compared with treatment 
with ΔEGFR+ TCR-I T cells in conjunction with the murinized 
monospecific anti-EpCAM antibody (44 ± 52 mm3 vs 346 ± 
113 mm3, P  =  .014 from day 55) (see Supplementary Table  2, 
available online, for a summary of P values) or with the anti-
body alone (44 ± 52 mm3 vs 464 ± 233 mm3, P =  .004 at day 44) 
(Figure 3A). The in vivo efficacy of the combined T cell and BiAb 
treatment was confirmed in a second in vivo study by treatment 
of mice with the ER-Ep BiAb alone, as well as with two different 
doses of the ER-Ep BiAb together with ACT (Figure 3B). The ER-Ep 
BiAb alone did not confer therapeutic efficacy, whereas ER-Ep 
BiAb together with ACT showed a dose-dependent effect with 
10 mg/kg of BiAb being more effective than 2 mg/kg (10 ± 7 mm3 
vs 205 ± 83 mm3, P = .038 at day 54) (see supplementary Table 3, 
available online, for a summary of P values; Figure  3B). Both 
low and high doses of ER-Ep BiAb plus ACT prolonged survival 
of tumor-bearing mice compared with ACT with a murinized 
monospecific anti-EpCAM antibody (median survival high dose 
BiAb 95 vs control 75 days, P < .001) (Figure 3C). Mice tolerated 
the treatment well with no obvious signs of toxicity. In addition, 
non–tumor-bearing animals treated with the combination regi-
men showed no diarrhea or weight loss (data not shown) during 
an observation period of 100 days. In line with these results, no 
increase in T cell infiltration was found in organs lacking the 
SV40 T antigen (Supplementary Figure 3A, available online).
Influence of the Combination Therapy on T Cell 
Infiltration Into the Tumor
To investigate the mechanisms contributing to tumor control or 
to escape from therapy, we analyzed by immunohistochemistry 
the tumors depicted in Figures 3, A and B, for the presence of 
infiltrating T cells (from mice which had to be killed because of 
a prespecified tumor-size threshold). Tumors from mice treated 
with ER-Ep BiAb plus ΔEGFR-transduced T cells contained more 
CD3+ T cells than the group treated with ΔEGFR-transduced T 
cells without BiAb (0.40 ± 0.42 vs 0.09 ± 0.14 per high power field, 
P = .021) (Supplementary Figure 3, B-D, available online).
Bispecific Antibody Enhances Recognition of Tumor 
Cells by TCR- and CAR-Transduced Human T Cells
To test if our strategy can also be applied to target human tumors, 
we used the previously described EGFR x c-Met bispecific antibody 
(ER-Met BiAb) (16) together with either ΔEGFR-transduced human 
T cells, the HLA-A2–tyrosinase-specific human T cell clone IVSB 
(17) or human CEA-CAR–specific T cells (Figure 4A) (11). We chose 
c-Met because of its wide expression on human tumor cells (18). 
The ER-Met BiAb retained ΔEGFR+ T cells to immobilized c-Met (57 
± 12 % vs 7 ± 2 %, P = .002) (Figure 4B), without affecting ΔEGFR- T 
cells (6 ± 2 % vs 5 ± 0.4 %, P = .280). Remarkably, retention of ΔEGFR-
transduced tyrosinase-specific IVSB T cells strongly enhanced rec-
ognition of the tyrosinase+ HLA-A2+ mel624 melanoma cells but not 
of the tyrosinase- HLA-A2+ melA375 melanoma cells, as measured 
by IFN-γ release by the T cells (877 ± 63 ng/mL vs 166 ± 27 ng/mL, P < 
.001) (Figure 4C). Similarly, coculture of ΔEGFR- and CEA-CAR–trans-
duced T cells with CEA+ LS174T colon cancer cells in the presence 
of ER-Met BiAb increased CAR-mediated T cell activation indicated 
by antigen-specific IFN-γ release; the effect was most prominent 
when using suboptimal numbers of anti–CEA-CAR T cells (IFN-γ 
release 330 ± 39 ng/mL vs 0 ± 0 ng/mL, P = .001) (Figure 4D). Thus, 
the ER-Met BiAb is able to enhance the TCR- or CAR-mediated acti-
vation of T cells by targeting T cells to tumor cells.
Discussion
Our study shows that, in mice, treatment with ER-Ep BiAb in 
conjunction with ACT of marker antigen–transduced tumor-spe-
cific T cells resulted in enhanced T cell–mediated tumor killing 
and in T cell accumulation in subcutaneous mGC8 tumors. This 
novel treatment approach also enhanced tumor recognition by 
human T cells via a tumor-specific TCR or CAR, suggesting the 
amenability of the strategy against human tumors. This is the 
first report demonstrating that a nonactivating BiAb is able to 
specifically accumulate tumor-specific T cells in the tumor with-
out the need of polyclonal T cell activation. The strategy has the 
potential to enhance safety of ACT by avoiding triggering of T 
cells of other specificities at sites distant to the tumor.
The principal amenability of targeting EpCAM+ murine and 
human tumors for recruitment and activation of T cells has 
previously been shown (19). This provided the basis for select-
ing EpCAM as a model antigen for BiAb therapy. Similarly, we 
used c-Met as a BiAb target because of its broad expression 
in human malignancies and because of the already proven 
employability of a c-Met–bispecific antibody (16,18). A  chal-
lenge in translating the combined ACT plus BiAb strategy into 
clinical application is the choice of an appropriate marker 
antigen for human T cell modification. Because ΔEGFR, as 
employed in the present study, has been described to be of low 
spontaneous immunogenicity (20), we selected it as a suitable 
human target in both murine and human tumor models. Given 
the favorable safety profile of EGFR-targeted antibody therapy, 
EGFR may be a suitable antigen for clinical application. In fact, 
ΔEGFR-transduced T cells are currently used as a safety switch 
in an adoptive T cell trial (NCT01815749) to permit T cell deple-
tion through EGFR-targeted antibodies if required. However, 
the ubiquitous EGFR expression and thus the targeting of T 
Table 1. Surface plasmon resonance analysis of antibody affinities to murine EpCAM and human EGFR ectodomains*
Antibody Analyte Ka, M-1s-1 kd, s-1 t ½, min KD, M
ER-Ep BiAb EpCAM 2.0 x 105 2.5 x 10–3 4.6 1.2 x 10–8
ER-Ep BiAb EGFR 1.1 x 106 5.7 x 10–3 2.0 5.5 x 10–9
Murinized antibody G8.8 EpCAM 2.2 x 105 1.3 x 10–2 0.9 6.1 x 10–8
Murinized antibody Mab225 EGFR 1.3 x 106 5.7 x 10–3 2.0 4.3 x 10–9
* Ka = association constant; t ½ = half life; EGFR = epithelial growth factor receptor; EpCAM = epithelial cell adhesion molecule; ER-Ep Biab = anti-EGFR x anti-EpCAM 
bispecific antibody; kd = dissociation constant; KD = dissociation equilibrium constant.
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cells to nontumor tissue may limit therapeutic benefit. Other T 
cell marker proteins will be needed to be explored before clini-
cal testing, such as EGFR variant 3, which is a tumor-specific 
mutation in EGFR, targetable by antibodies and found only in 
certain tumor entities such as glioblastoma (21).
The choice of tumor antigen specificity for the BiAb design is 
also challenging, because most tumor-associated antigens are 
not tumor specific (22). In the absence of ideal targets, both the 
TCR of the adoptively transferred T cells and the BiAb-targeted 
tumor antigen should be selected on the basis of a restricted 
expression pattern. However, even targeting less abundant 
antigens may result in severe side effects (23). In our strategy, 
the absence of an activating component in the BiAb design, 
such as a CD3 binding domain, and the specificity of the T cells 
for a distinct tumor antigen presented in the context of major 
histocompatibility complex (MHC) class I are likely to enhance 
therapeutic safety. Avoiding unwanted, undirected T cell acti-
vation remains a major challenge with respect to the T cell 
recruiting BiAb.
Previous clinical studies have used BiAb to recruit T cells 
to tumor cells in patients (10,24,25). A  major difference to 
our study is that all previous approaches used the activating 
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Figure 2. Linking of T cells to tumor cells and induction of specific lysis by anti-epidermal growth factor receptor (EGFR) x anti-EpCAM bispecific antibody. A) Confluent 
EpCAM-positive 4T1 cells were incubated with ΔEGFR-transduced calcein-labelled B3Z T cells in the presence of the anti-EGFR x anti-EpCAM bispecific antibody (ER-Ep BiAb, 
10 µg/mL) or the control anti-EGFR x anti-digoxigenin bispecific antibody (ER-Dig BiAb, 10 µg/mL). The number of labeled B3Z T cells retained after washing was quantified by 
the amount of remaining fluorescent calcein. Mean values of three independent experiments performed each in triplicates are shown (n = 3). Error bars are standard devia-
tion; P values are calculated using two-sided, unpaired Student’s t test. B and C) Representative fluorescence microscopy images depicting fluorescently (green) labelled T cells 
retained in proximity to the tumor cells when the anti-EGFR x anti-EpCAM bispecific antibody is applied (B) vs a control antibody (C) at 10 x magnitude; scale bar represents 
250 μm. D) Lysis mediated by cross-linking of the T cell to the tumor cell by the anti-EGFR x anti-EpCAM bispecific antibody measured by calcein release. T cells with a trans-
genic TCR specific for SV40 T antigen or with the OT1-transgenic TCR specific for ovalbumin or wild type (WT) T cells were incubated overnight with or without the anti-EGFR x 
anti-EpCAM bispecific antibody or anti-EGFR x anti-digoxigenin bispecific antibody and with tumor cells expressing EpCAM (cell lines 4T1 and mGC8), SV40 T antigen (mGC8), 
or neither (B16). Mean results of four independent experiments are shown. Error bars represent standard deviation. P values were calculated by the two-sided Student’s t test.
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Figure 3. In vivo efficacy of the anti-EGFR x anti-EpCAM BiAb combined with adoptive transfer of ΔEGFR-transduced T cells. A) Anti–epidermal growth factor recep-
tor (EGFR) x anti-EpCAM bispecific antibody (ER-Ep BiAb) combined with transfer of ΔEGFR-transduced T cells retards growth of subcutaneous mGC8 tumors. Mice 
received either PBS i.v. (group 1, n = 6), anti-EpCAM antibody 300 µg i.v. (group 2, n = 6,), 107 ΔEGFR-transduced TCR-I expressing T cells i.v. together with 300 µg 
anti-EpCAM antibody i.v. (group 3, n = 6), or 107 ΔEGFR-transduced TCR-I expressing T cells i.v. together with 300 µg of anti-EGFR x anti-EpCAM bispecific antibody 
i.v. (group 4, n = 11) on days 27 and 34 (represented by the arrows) from tumor induction. Error bars represent standard deviation. Statistics were calculated using 
two-way analysis of variance (ANOVA) with correction for multiple testing by the Bonferroni method. B) Therapeutic efficacy of combined application of anti-EGFR 
x anti-EpCAM bispecific antibody and ΔEGFR-transduced T cells is dose dependent. Mice received either PBS i.v. (group 1, n = 7), anti-EpCAM antibody i.v. (group 2, 
300 µg, n = 7), anti-EGFR x anti-EpCAM bispecific antibody i.v. (group 3, 300 µg, n = 6), anti-EpCAM antibody plus anti-EGFR antibody i.v. together with 5 x 106 ΔEGFR-
transduced T cells (group 4, 300 µg, n = 7), a low dose (60 µg per injection) of anti-EGFR x anti-EpCAM bispecific antibody together with 5 x106 ΔEGFR-transduced T 
cells (group 5, n = 6), or a high dose (300 µg per injection, split in 100 µg together with the T cells i.v. and 200 µg i.p. given simultaneously) of anti-EGFR x anti-EpCAM 
bispecific antibody together with 5 x 106 ΔEGFR-transduced T cells (group 6, each n = 12). Treatment was applied twice, on days 27 and 35 after tumor induction 
(represented by the arrows). Error bars represent standard deviation. Statistics were calculated using two-way ANOVA with correction for multiple testing by the 
Bonferroni method. C) Survival curves for the treatment groups in experiment (B). Survival of the groups treated with the combination of anti-EGFR x anti-EpCAM 
bispecific antibody and transduced T cells is longer than survival in any of the control groups (P < .001 for comparison of median survival by log-rank test with the 
groups treated with anti-EGFR x anti-EpCAM bispecific antibody, anti-EpCAM antibody, as well as anti-EpCAM and anti-EGFR antibodies with ΔEGFR-transduced 
T cells; no statistically significant difference between high and low anti-EGFR x anti-EpCAM bispecific antibody dose plus ΔEGFR-transduced T cells groups). All 
statistical tests were two-sided.
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component of the BiAb, eg, an activating anti-CD3 antibody. 
In contrast, the present study is the first to show that a non-
activating BiAb physically linking T cells to tumor cells can 
enhance the efficacy of adoptively transferred tumor-specific 
T cells and favor T cell recruitment and/or retention in the 
tumor. However, additional studies using primary human 
samples in xenograft models are needed to move the concept 
towards clinical application.
An important advantage of the present approach, com-
pared with conventional T cell recruiting BiAb, is the selective 
recruitment of adoptively transferred tumor antigen-specific T 
cells in comparison with the recruitment of all CD3-positive T 
cells. Our strategy is potentially adaptable to a variety of T cells, 
such as tumor-infiltrating lymphocytes, or, as shown in the pre-
sent study, to TCR- and CAR-modified T cells. Such modified 
T cells are currently under investigation in clinical trials and 
show promising efficacy (26,27). Thus potential combination 
candidates for clinical development of the therapeutic principle 
may include T cells transduced with a TCR, eg, NY-ESO-1, or with 
a CAR, eg, recognizing CEA or CD19.
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Figure 4. Linking of T cells and tumor cells and enhancement of tumor cell recognition by anti–epidermal growth factor receptor (EGFR) x anti-c-Met bispecific antibody. 
A) Schematic diagram of bispecific antibody-enhanced binding of tumor antigen–specific human T cells to tumor cells. The anti-EGFR x anti-c-Met bispecific antibody (ER-Met 
BiAb) in a two-plus-one format contains one binding site for c-Met (antihuman c-Met 5D5 antibody), which is expressed on the tumor cell surface, and two binding sites for a 
truncated form of EGFR, which is expressed by the transduced human T cells. The T cell receptor of the transduced T cells is specific for tyrosinase in the context of HLA-A2, 
which is presented in the context of MHC class I by the tumor cell. Alternatively, the chimeric antigen receptor (CAR) specific for CEA expressed on the tumor cell is targeted. 
Cross-linking by anti-EGFR x anti-c-Met bispecific antibody may increase or stabilize T cell–tumor cell contact established by the T cell receptor–MHC class I or the CAR-CEA 
interaction. B) T cell adhesion to c-Met. Human T cell line (Jurkat) was transduced with EGFR, labelled with calcein and preincubated with or without anti-EGFR x anti-c-Met 
bispecific antibody prior to incubation on a plate coated with recombinant c-Met. Untransduced human T cell line with or without anti-EGFR x anti-c-Met bispecific antibody 
were used as controls. After washing, calcein was quantified in each well. Fluorescence was normalized to unwashed wells (100% fluorescence). Results are the mean of three 
independent experiments. Error bars represent standard deviation; P values were calculated by the two-sided unpaired Student’s t test. C) ΔEGFR-transduced or untransduced 
clonally-derived tyrosinase-specific IVSB T cells were incubated with EGFR-specific antibody and adhesion was performed by magnetic cell separation (MACS). Retained 
cells were cocultured for 48 hours at a 10:1 ratio with tyrosinase+, HLA-A2+ mel624.38 cells or with tyrosinase-, HLA-A2+ MelA375 cells. T cell activation was assessed by IFN-γ 
release. Results shown are the mean of triplicates and are representative of three independent experiments. Error bars represent standard deviation; P values were calculated 
by two-sided unpaired Student’s t test. D) ΔEGFR- and CEA-CAR–transduced primary human T cells or untransduced T cells were preincubated with or without anti-EGFR x 
anti-c-Met bispecific antibody (10 μg/mL) and cocultured for 48 hours with CEA+ LS174T cells. IFN-γ was quantified by ELISA. Results shown are the mean of triplicates and are 
representative of two independent experiments. Error bars represent standard deviation; P values were calculated by two-sided unpaired Student’s t test.
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